149 related articles for article (PubMed ID: 36324591)
1. Genomic profiling of non-small cell lung cancer with the rare pulmonary lymphangitic carcinomatosis and clinical outcome of the exploratory anlotinib treatment.
Dong C; Cheng W; Zhang M; Li S; Zhao L; Chen D; Qin Y; Xiao M; Fang S
Front Oncol; 2022; 12():992596. PubMed ID: 36324591
[TBL] [Abstract][Full Text] [Related]
2. Etoposide/platinum plus anlotinib for patients with transformed small-cell lung cancer from EGFR-mutant lung adenocarcinoma after EGFR-TKI resistance: a retrospective and observational study.
Ding J; Leng Z; Gu H; Jing X; Song Y
Front Oncol; 2023; 13():1153131. PubMed ID: 37361601
[TBL] [Abstract][Full Text] [Related]
3. Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study.
Wang W; Xu C; Chen H; Jia J; Wang L; Feng H; Wang H; Song Z; Yang N; Zhang Y
Lung Cancer; 2021 May; 155():20-27. PubMed ID: 33714778
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of anlotinib combined with carboplatin and pemetrexed as first-line induction therapy followed by anlotinib plus pemetrexed as maintenance therapy in
He Z; Yang X; Ma T; Yang Q; Zhang C; Chen Y; Wang P; D'Incecco A; Metro G; Uematsu S; Wang Q
Transl Lung Cancer Res; 2022 Aug; 11(8):1657-1666. PubMed ID: 36090635
[TBL] [Abstract][Full Text] [Related]
5. The Landscape of Actionable Genomic Alterations by Next-Generation Sequencing in Tumor Tissue Versus Circulating Tumor DNA in Chinese Patients With Non-Small Cell Lung Cancer.
Cai J; Jiang H; Li S; Yan X; Wang M; Li N; Zhu C; Dong H; Wang D; Xu Y; Xie H; Wu S; Lou J; Zhao J; Li Q
Front Oncol; 2021; 11():751106. PubMed ID: 35273907
[TBL] [Abstract][Full Text] [Related]
6. The co-mutation of
Zhang Y; Li S; Lyu Z; Cai J; Zheng N; Li Y; Xu T; Zeng H
J Thorac Dis; 2022 Jan; 14(1):185-193. PubMed ID: 35242380
[TBL] [Abstract][Full Text] [Related]
7. Genomic landscape and prognosis of patients with
Fan Z; Zhang Q; Feng L; Wang L; Zhou X; Han J; Li D; Liu J; Zhang X; Zuo J; Zou X; Cai Y; Sun Y; Wang Y
Ann Transl Med; 2022 Feb; 10(4):188. PubMed ID: 35280362
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study.
Zhong Q; Liu Z
Cancer Manag Res; 2021; 13():4115-4128. PubMed ID: 34045898
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M-positive NSCLC: A retrospective study.
Zhou B; Gong Q; Li B; Qie HL; Li W; Jiang HT; Li HF
J Clin Pharm Ther; 2022 May; 47(5):643-651. PubMed ID: 35023208
[TBL] [Abstract][Full Text] [Related]
10. Anlotinib Combined with S-1 in Third- or Later-Line Stage IV Non-Small Cell Lung Cancer Treatment: A Phase II Clinical Trial.
Xiang M; Yang X; Ren S; Du H; Geng L; Yuan L; Wen Y; Lin B; Li J; Zhang Y; Feng G; Du X
Oncologist; 2021 Dec; 26(12):e2130-e2135. PubMed ID: 34423518
[TBL] [Abstract][Full Text] [Related]
11. Anlotinib or platinum-pemetrexed as second-line therapy in EGFR T790M-negative lung cancer.
Zhong RB; Xu JL; Lou YQ; Chu TQ; Zhong H; Han BH
Ann Palliat Med; 2020 Jul; 9(4):1681-1687. PubMed ID: 32575999
[TBL] [Abstract][Full Text] [Related]
12. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.
Han B; Li K; Wang Q; Zhang L; Shi J; Wang Z; Cheng Y; He J; Shi Y; Zhao Y; Yu H; Zhao Y; Chen W; Luo Y; Wu L; Wang X; Pirker R; Nan K; Jin F; Dong J; Li B; Sun Y
JAMA Oncol; 2018 Nov; 4(11):1569-1575. PubMed ID: 30098152
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study.
Chu T; Zhang W; Zhang B; Zhong R; Zhang X; Gu A; Shi C; Wang H; Xiong L; Lu J; Qian J; Zhang Y; Dong Y; Teng J; Gao Z; Wang W; Shen Y; Nie W; Lim JU; Mehta HJ; Neal JW; Lou Y; Xu J; Zhong H; Han B
Transl Lung Cancer Res; 2022 Jul; 11(7):1394-1404. PubMed ID: 35958322
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study.
Wang W; Shao L; Xu Y; Song Z; Lou G; Zhang Y; Chen M
BMC Pulm Med; 2022 May; 22(1):179. PubMed ID: 35524294
[TBL] [Abstract][Full Text] [Related]
15. Genomic characteristics in Chinese non-small cell lung cancer patients and its value in prediction of postoperative prognosis.
Zhang B; Zhang L; Yue D; Li C; Zhang H; Ye J; Gao L; Zhao X; Chen C; Huo Y; Pang C; Li Y; Chen Y; Chuai S; Zhang Z; Giaccone G; Wang C
Transl Lung Cancer Res; 2020 Aug; 9(4):1187-1201. PubMed ID: 32953497
[TBL] [Abstract][Full Text] [Related]
16. Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer.
Xiong Q; Qin B; Xin L; Yang B; Song Q; Wang Y; Zhang S; Hu Y
Front Oncol; 2021; 11():659380. PubMed ID: 34395243
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Gefitinib Plus Anlotinib for Patients with EGFR Positive Advanced Non-Small-Cell Lung Cancer: A Retrospective Exploratory Study.
Hu WX; Peng JC; Wang Y; Jin H; Geng N
Int J Gen Med; 2022; 15():4453-4464. PubMed ID: 35509604
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer.
Zhong Y; Wei Q; Lu Y; Tang X; Wang Z; Chen L
J Thorac Dis; 2020 Oct; 12(10):6016-6022. PubMed ID: 33209434
[TBL] [Abstract][Full Text] [Related]
19. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
[TBL] [Abstract][Full Text] [Related]
20. Fluorodeoxyglucose Uptake in Advanced Non-small Cell Lung Cancer With and Without Pulmonary Lymphangitic Carcinomatosis.
Ooi H; Chen CY; Hsiao YC; Huang WS; Hsieh BT
Anticancer Res; 2016 Aug; 36(8):4313-20. PubMed ID: 27466550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]